This article is more than 5 years old. Information may no longer be current.

Iluvien meets cost-effectiveness threshold for pseudophakic DME patients, NICE panel finds

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The appraisal committee of the National Institute for Health and Care Excellence in the United Kingdom determined a patient access scheme for Iluvien meets the cost-effectiveness threshold for treatment of pseudophakic patients with chronic diabetic macular edema, according to a news release.

The patient access scheme for Iluvien (sustained-release fluocinolone acetonide, Alimera Sciences) was proposed after NICE issued guidance in January that it could not recommend the treatment based on cost-effectiveness.

The committee said the patient access scheme shows the cost-effectiveness threshold has been met and recommended a change to the published guidance.

The U.K., Austria, France, Portugal, Spain and Germany have granted national licenses for Iluvien after Alimera successfully completed the decentralized procedure. The treatment has not been approved by the U.S. Food and Drug Administration.